PT-141 for men: an unfinished record
The early erectile response deserves a place in the record. So does the approval that never followed.
An effect worth pursuing
The early PT-141 paper reported erections in rats, nonhuman primates and men with erectile dysfunction. Later, a placebo-controlled nasal-spray study included healthy men and men with mild-to-moderate erectile dysfunction. At study amounts above 7 mg, an erectile response occurred more often than with placebo; first erections appeared at about 30 minutes.
Those are observations from a particular formulation and study population. I grant them their place in the history without turning them into an instruction for someone holding a different preparation. The dosage page explains why the nasal-spray figures do not supply a personal injection amount.
The same investigation reported a terminal half-life of 1.85 to 2.09 hours. That measures how the blood concentration falls; the duration of an erection or a change in desire requires a separate measurement.
A different starting point from blood-flow medicines
PT-141 works centrally, whereas PDE-5 inhibitors act on vascular smooth muscle to improve erectile blood flow. The melanocortin overview explains the distinction. It does not establish superiority, and neither mechanism makes the other irrelevant.
Researchers studied PT-141 given under the skin in healthy men and men whose response to sildenafil was inadequate. Another small combination study found an enhanced erectile response with intranasal PT-141 and sildenafil together. These experiments left the comparison of routine treatment choices unsettled.
The seductive leap is from “a different mechanism” to “the answer when everything else fails.” I’m unconvinced by that leap. In particular, the salvage study published in 2008 carries a 2023 Expression of Concern; its reported benefit is disputed. The results page leaves that notice beside the figures.
Has PT-141 been approved for men?
No. PT-141 (bremelanotide) is approved in the United States only for acquired, generalized hypoactive sexual desire disorder in premenopausal women [7]. It is not approved for men, not approved for postmenopausal women, and not approved to enhance performance in anyone [7]. The male erectile-dysfunction program did not reach approval.
That distinction matters for honesty. The studies in men are genuine and the early erectile effect was real [1][8] — but 'studied in men' is not the same as 'approved for men.' A separate point worth flagging: material sold online as a 'PT-141 research chemical' is not the approved medicine and is not quality-controlled for identity, purity, or strength [7]. The approved drug and the gray-market peptide are not interchangeable.
That distinction is also where the word in this domain's name stops describing PT-141 accurately. 'Shop' suggests choosing a product at checkout, but the approved bremelanotide injection needs a prescriber's order; its FDA label covers only premenopausal women with acquired, generalized hypoactive sexual desire disorder [7]. That approval does not extend to other populations or other uses. For PT-141 (bremelanotide), Promise Peptides provides prescription care at mypromise.com today: a licensed U.S. clinician examines each case, and some requests end without a prescription. State rules can allow one treatment while excluding another, and this care extends only to patients in the United States. Mentioning this route does not endorse it, and the compounded medicine lacks the FDA approval held by the approved injection. Both prescription routes put a clinician's decision before dispensing; research-labelled PT-141 remains on sale without that clinical review. That is why 'shop' describes this site's name, not the way prescription care is decided.
PT-141 for women followed a different route
The large RECONNECT trials enrolled 1,267 premenopausal women with hypoactive sexual desire disorder and measured desire and distress over 24 weeks. They were not trials of male erection problems. A 52-week extension followed the women’s program, and a smaller brain-imaging study later examined sexual processing in women with the same diagnosis.
That is how the approval record became much stronger for a particular group of women than for men. The evidence applies to the population studied; benefit in another population remains a separate question. Online accounts of male use remain anecdotal; this program’s clinical benefit-and-safety questions remain unanswered by those accounts.